Oral News and Research

RSS

Rapid increase in number of HPV-related oral cancers in the UK

The number of oral cancer cases diagnosed each year in the UK has risen above 6,000 for the first time, new figures from Cancer Research UK show today.

16 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

What's in store at the Supreme Court

News outlets report on the issues in play when the high court hears the health law oral arguments later this month, how particular justices might form their opinions and lay out the new, all-or-nothing position adopted by the U.S. Chamber of Commerce.

16 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

Republicans, Democrats spin health law as Supreme Court review approaches

With oral arguments set for later this month, the health law is getting more attention from Republicans and the administration as well as from news outlets, which are examining various aspects of the upcoming legal proceedings.

15 Mar 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

Researchers identify epigenetic signatures within reprogrammed skin cells

A research team has identified epigenetic signatures, markers on DNA that control transient changes in gene expression, within reprogrammed skin cells.

15 Mar 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

New rule ensuring equal access for ESRD patients receives DPC praise

Dialysis Patient Citizens (DPC), the nation's largest patient-led organization representing dialysis patients, applauded the Administration for taking steps to solidify a key provision that will ensure end stage renal disease (ESRD) patients have equal access to private coverage as Affordable Care Act reforms are implemented.

14 Mar 2012

African Americans in Georgia found to have poor survival rates from cancer

African Americans in Georgia, especially in rural areas, have drastically poorer survival rates from cancer. These disparities are much larger when compared to national data, according to the findings from a study recently published in the journal Cancer by a team of researchers in the University of Georgia College of Public Health.

14 Mar 2012

Healthcare exchange regulations announced

The U.S. government this Monday released broad new operating rules for state-run health insurance exchanges, which form a key part of the 2010 federal healthcare reform law. The reforms would face Supreme Court hearings in just two weeks.

14 Mar 2012

Bend Research announces licensing agreement with Affinium

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.

13 Mar 2012

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

New recovery protocol treats heart failure patients with LVADs

Some patients with advanced heart failure caused by cardiomyopathy, the deterioration of function of the heart muscle, are benefitting from a new recovery protocol at the University of Louisville and Jewish Hospital, a part of KentuckyOne Health.

13 Mar 2012

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

MedivirAB a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

13 Mar 2012

Diacetylmorphine more cost-effective than MMT in treating street heroin users

Medically prescribed heroin is more cost-effective than methadone for treating long-term street heroin users, according to a new study by researchers at Providence Health Care and the University of British Columbia.

13 Mar 2012

FTY720 improves locomotor recovery in mice with SCI

A new study suggests that administering FTY720, an oral drug that has shown promise in trials for human multiple sclerosis, significantly improves locomotor recovery in mice with spinal cord injury.

13 Mar 2012

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

13 Mar 2012

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

12 Mar 2012

FDA approves Organogenesis oral soft tissue regeneration product, GINTUIT

Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue).

12 Mar 2012